Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Ma, Jian ^a   Wang, Shuiliang ^b   Zhao, Ming ^c   Deng, Xin Sheng ^b   Lee, Choon Kee ^b   Yu, Xiao Dan ^c   Liu, Bolin ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CLADRIBINE; DNA FRAGMENT; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN INHIBITOR; S 3I 201; STAT3 PROTEIN; UNCLASSIFIED DRUG; AMINOSALICYLIC ACID DERIVATIVE; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; NSC 74859; STAT3 PROTEIN, HUMAN; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL SPECIFICITY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MITOSIS INHIBITION; MONOTHERAPY; MULTIPLE MYELOMA; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; BIOSYNTHESIS; CELL CYCLE; CELL DIVISION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; PATHOLOGY; TUMOR CELL LINE;

AMINOSALICYLIC ACIDS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZENESULFONATES; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CLADRIBINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; INHIBITORY CONCENTRATION 50; MULTIPLE MYELOMA; NEOPLASM PROTEINS; STAT3 TRANSCRIPTION FACTOR;

EID: 79959248152     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-255     Document Type: Article

References (44)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004, 351:1860-1873. 10.1056/NEJMra041875, 15509819.
2. Naumann F, Weingart O, Kruse E, Schulz H, Bohlius J, Hulsewede H, Engert A. Fifth biannual report of the cochrane haematologic malignancies group--focus on multiple myeloma. J Natl Cancer Inst 2006, 98:E2-E. 10.1093/jnci/djj328, 16912255.
3. Robak T, Korycka A, Kasznicki M, Wrzesien-Kus A, Smolewski P. Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications. Curr Cancer Drug Targets 2005, 5(6):421-444. 10.2174/1568009054863618, 16178817.
4. Robak T, Lech-Maranda E, Korycka A, Robak E. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr Med Chem 2006, 13:3165-3189. 10.2174/092986706778742918, 17168705.
5. Hjertner O, Borset M, Waage A. Comparison of the effects of 2-chlorodeoxyadenosine and melphalan on myeloma cell lines. Leuk Res 1996, 20:155-160. 10.1016/0145-2126(95)00128-X, 8628014.
6. Gidron A, Tallman MS. 2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up. Leuk Lymphoma 2006, 47(11):2301-2307. 10.1080/10428190600822052, 17107901.
7. Huynh E, Sigal D, Saven A. Cladribine in the treatment of hairy cell leukemia: initial and subsequent results. Leuk Lymphoma 2009, 50(Suppl 1):12-17.
8. Chadha P, Rademaker AW, Mendiratta P, Kim B, Evanchuk DM, Hakimian D, Peterson LC, Tallman MS. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 2005, 106:241-246. 10.1182/blood-2005-01-0173, 15761021.
9. Cheson BD, Sorensen JM, Vena DA, Montello MJ, Barrett JA, Damasio E, Tallman M, Annino L, Connors J, Coiffier B, Lauria F. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998, 16:3007-3015.
10. Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004, 18:1476-1481. 10.1038/sj.leu.2403418, 15229616.
11. Bertazzoni P, Rabascio C, Gigli F, Calabrese L, Radice D, Calleri A, Gregato G, Negri M, Liptrott SJ, Bassi S, Nassi L, Sammassimo S, Laszlo D, Preda L, Pruneri G, Orlando L, Martinelli G. Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients. Leuk Lymphoma 2010, 51:1485-1493. 10.3109/10428194.2010.495799, 20578816.
12. Leupin N, Schuller JC, Solenthaler M, Heim D, Rovo A, Beretta K, Gregor M, Bargetzi MJ, Brauchli P, Himmelmann A, Hanselmann S, Zenhäusern R. Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02). Leuk Lymphoma 2010, 51:613-619. 10.3109/10428191003624231, 20218808.
13. Sigal DS, Miller HJ, Schram ED, Saven A. Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood 2010, 116:2884-2896. 10.1182/blood-2010-02-246140, 20634380.
14. Dimopoulos MA, Kantarjian H, Estey E, O'Brien S, Delasalle K, Keating MJ, Freireich EJ, Alexanian R. Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 1993, 118:195-198.
15. Dimopoulos MA, Kantarjian HM, Estey EH, Alexanian R. 2-Chlorodeoxyadenosine in the treatment of multiple myeloma. Blood 1992, 80:1626.
16. Niesvizky R, Siegel D, Michaeli J. 2-Chlorodeoxyadenosine for multiple myeloma. Blood 1993, 81:868-869.
17. Niesvizky R, Siegel D, Michaeli J. Biology and treatment of multiple myeloma. Blood Rev 1993, 7:24-33. 10.1016/0268-960X(93)90021-U, 8467229.
18. Krett NL, Ayres M, Nabhan C, Ma C, Nowak B, Nawrocki S, Rosen ST, Gandhi V. In vitro assessment of nucleoside analogs in multiple myeloma. Cancer Chemother Pharmacol 2004, 54:113-121.
19. Nagourney RA, Evans SS, Messenger JC, Su YZ, Weisenthal LM. 2 chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms. Br J Cancer 1993, 67:10-14. 10.1038/bjc.1993.3, 1968239, 8094002.
20. Bagley RG, Roth S, Kurtzberg LS, Rouleau C, Yao M, Crawford J, Krumbholz R, Lovett D, Schmid S, Teicher BA. Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs. Int J Oncol 2009, 34:1329-1340.
21. Johnston JB. Mechanism of Action of Pentostatin and Cladribine in Hairy Cell Leukemia. Leuk Lymphoma 2011,
22. Chesi M, Bergsagel PL. Epigenetics and microRNAs combine to modulate the MDM2/p53 axis in myeloma. Cancer Cell 2010, 18:299-300. 10.1016/j.ccr.2010.10.004, 20951939.
23. Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM, Hofmainster C, Alder H, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010, 18:367-381. 10.1016/j.ccr.2010.09.005, 20951946.
24. Burger R, Bakker F, Guenther A, Baum W, Schmidt-Arras D, Hideshima T, Tai YT, Shringarpure R, Catley L, Senaldi G, Gramatzki M, Anderson KC. Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival. Br J Haematol 2003, 123:869-878. 10.1046/j.1365-2141.2003.04686.x, 14632778.
25. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115. 10.1016/S1074-7613(00)80011-4, 10023775.
26. Hodge DR, Xiao W, Wang LH, Li D, Farrar WL. Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in multiple myeloma cells. Cancer Biol Ther 2004, 3:188-194.
27. Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 2008, 18:254-267. 10.1038/cr.2008.18, 2610254, 18227858.
28. Lee CK, Wang S, Huang X, Ryder J, Liu B. HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells. Cancer Lett 2010, 296:233-240. 10.1016/j.canlet.2010.04.014, 20447761.
29. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE. Stat3 as an oncogene. Cell 1999, 98:295-303. 10.1016/S0092-8674(00)81959-5, 10458605.
30. Yu H, Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer 2004, 4:97-105. 10.1038/nrc1275, 14964307.
31. Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we?. Expert Opin Investig Drugs 2009, 18:45-56. 10.1517/13543780802565791, 2610472, 19053881.
32. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, Yip ML, Jove R, McLaughlin MM, Lawrence NJ, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 2007, 104:7391-7396. 10.1073/pnas.0609757104, 1863497, 17463090.
33. Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. Cancer Res 1991, 51:5570-5572.
34. Sonderegger T, Betticher DC, Cerny T, Lauterburg BH. Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. Cancer Chemother Pharmacol 2000, 46:40-42. 10.1007/s002800000129, 10912576.
35. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007, 7:585-598. 10.1038/nrc2189, 17646864.
36. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009, 23:10-24. 10.1038/leu.2008.259, 18843284.
37. Edwards A, Li J, Atadja P, Bhalla K, Haura EB. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther 2007, 6:2515-2524. 10.1158/1535-7163.MCT-06-0761, 17876048.
38. Lin TY, Fenger J, Murahari S, Bear MD, Kulp SK, Wang D, Chen CS, Kisseberth WC, London CA. AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit. Blood 2010, 115:4217-4225. 10.1182/blood-2009-07-231985, 20233974.
39. Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Focus on multiple myeloma. Cancer Cell 2004, 6:439-444. 10.1016/j.ccr.2004.10.020, 15542427.
40. Sprynski AC, Hose D, Caillot L, Reme T, Shaughnessy JD, Barlogie B, Seckinger A, Moreaux J, Hundemer M, Jourdan M, Meissner T, Jauch A, Mahtouk K, Kassambara A, Bertsch U, Rossi JF, Goldschmidt H, Klein B. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 2009, 113:4614-4626. 10.1182/blood-2008-07-170464, 2691749, 19228610.
41. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, García-Echeverría C, Pearson MA, Hofmann F, Anderson KC, Kung AL. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004, 5:221-230. 10.1016/S1535-6108(04)00050-9, 15050914.
42. Menu E, van Valckenborgh E, van Camp B, Vanderkerken K. The role of the insulin-like growth factor 1 receptor axis in multiple myeloma. Arch Physiol Biochem 2009, 115:49-57. 10.1080/13813450902736583, 19234898.
43. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, Fan Z. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003, 22:3205-3212. 10.1038/sj.onc.1206394, 12761490.
44. Wang S, Huang X, Lee CK, Liu B. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene 2010, 29:4225-4236. 10.1038/onc.2010.180, 20498641.